Multivariable analysis, after adjusting for age, gender, tumor diameter, tumor location, pathological type, extrapulmonary metastasis, and tumor stage, indicated that DEB-BACE therapy was an independent protective factor for both OS (adjusted HR = 0.45, 95% CI: 0.30–0.67, P < 0.001) and hemoptysis-free survival (adjusted HR = 0.48, 95% CI: 0.34–0.68, P < 0.001). Here, BACE1 is linked to neoplasm.